Dagdeviren, C., Ramadi, K., Joe, P., Spencer, K., Schwerdt, H., Shimazu, H., Delcasso, S., Amemori, K., Lopez, C., Graybiel, A. M., Cima, M. J.†, Langer, R.†, Science Translational Medicine, 10(425), 2018.

Abstract

MiND(S)-controlled drug delivery: More effective and better-tolerated pharmacological therapies are needed for neurological disorders. Current treatments often rely on systemic administration, resulting in increased risk of toxicity and adverse effects due to off-target drug distribution. Dagdeviren et al. combined intracranial electroencephalogram (EEG) recording with drug delivery in a miniaturized implantable system called MiNDS. MiNDS achieved controlled drug delivery in deep brain structures with high temporal and spatial resolution while monitoring local neuronal activity in rodents and nonhuman primates. If adopted into clinical practice, MiNDS could improve therapeutic outcomes and minimize adverse effects over currently available drug delivery methods for neurological disorders.